



Communiqué de presse,  
St Cloud, le 20 septembre 2022

---

## **Exclusive agreement with Berlin Chemie for Sitavig® in Eastern Europe and the CIS region.**

---

Berlin Chemie and Vectans Pharma have signed an exclusive licensing agreement whereby Berlin Chemie will have the rights to register and commercialize Sitavig® (Acyclovir Lauriad®), in Eastern Europe and the CIS region, expanding the international scope of Sitavig® to 30 additional countries\*.

Sitavig® is the first approved one-per-episode acyclovir, indicated for the treatment of recurrent herpes labialis (cold sores) in adults with frequent episodes.

Sitavig® is currently marketed as a prescription drug in the US but is now in transition to becoming a non-prescription or “Over the Counter (OTC)” drug in many markets. It has already been approved as OTC drug in France and Italy and the application is currently in progress in many European countries.

Cold sores – also called fever blisters – is a common and recurring condition that affects about 20% of the population. It is caused by the herpes simplex virus and the outbreaks are often triggered by various factors, as sunshine exposure, tiredness, stress, or menstrual periods, and often preceded by prodromal (warning) signs. During outbreaks, the sores are contagious from the first moment of tingling and can spread from person to person by close contact, such as kissing. The duration of an episode of herpes is 7 to 14 days.

The new therapeutic approach uses an innovative delivery system based on a mucoadhesive buccal tablet (Lauriad® technology). This ensures an early and extended release, for at least 16 hours of a high concentration of the active substance at the site of the infection. Given the concentrations reached in a day at the time and at the site of viral replication, a single tablet is enough for treatment. The targeted approach reduces the risk of drug interactions and systemic effects, improving greatly patient’s compliance.

### **About Vectans Pharma:**

Vectans Pharma is a French pharmaceutical company with an international reach, specialized in the development of muco-adhesive drugs, and offering new therapeutic perspectives to the patients. Thanks to its innovative platform, Lauriad®, our company ensures the development of new drugs and, with its international partners, the commercialization of Sitavig® and Loramyc® worldwide. Vectans Pharma delivers life-changing treatments, respectful of both humans and the environment, that improve patient access and experience around the world.

For more information about Vectans Pharma, please visit <https://www.vectanspharma.com/>

**About Berlin Chemie:**

For over 100 years, BERLIN-CHEMIE has stood for innovative research and production of newly developed as well as proven pharmaceutical products. Committed to health, its goal is to introduce new drugs to help ill patients and improve their quality of life.

As part of the global MENARINI Group, the leading Italian pharmaceutical company, BERLIN-CHEMIE is responsible for the pharmaceutical markets in Germany, Eastern Europe and the CIS region.

For more information, please visit <https://www.berlin-chemie.de/>

\*Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia, Armenia, Belarus, Kazakhstan, Kyrgyzstan, Russia, Albania, Azerbaijan, Bosnia Herzegovina, Georgia, Kosovo, Moldova, Mongolia, Montenegro, North Macedonia, Serbia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.